Ascletis' NDA for Its All-oral HCV Treatment Accepted by CFDA

(firmenpresse) - Hangzhou and Shaoxing, China , Aug 1, 2018 - (ACN Newswire) - Ascletis announced today it has received the acceptance letter from the China Food and Drug Administration (CFDA) for Ravidasvir (RDV) new drug application (NDA). Ravidasvir in combination with Ganovo (RDV/DNV Regimen) is the first all-oral interferon-free HCV regimen developed by a domestic company in China. Phase II/III clinical trial has shown that RDV/DNV Regimen demonstrated a cure rate of 99 % ( SVR12) with a short treatment duration of 12 weeks in genotype 1 patients. In patients with baseline NS5A resistance mutations, RDV/DNV Regimen demonstrated a cure rate of 100% (SVR12).

"Ascletis was successfully listed this morning on Hong Kong Exchange as the first ever pre-revenue biotech. The NDA for our all-oral HCV regimen was accepted by CFDA in the afternoon." Jinzi J. Wu, Ph.D., Ascletis' founder, President and CEO, commented, "Two significant accomplishments on the same day reflect our unremitting effort to provide affordable and effective HCV cures to the patients and to fulfill our commitment to the investors."

Ganovo Regimen, Ascletis' first breakthrough HCV regimen, was approved on June 8 and launched on June 27, 19 days after the approval. The acceptance of the NDA for its all-oral HCV regimen enables Ascletis soon to provide two HCV treatment options for Chinese patients, strengthening its leading position in China's HCV field.


Topic: Press release summary
Sectors: Daily Finance, Daily News, BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network

Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: acnnewswire
Datum: 02.08.2018 - 09:57 Uhr
Sprache: Deutsch
News-ID 579078
Anzahl Zeichen: 1756

contact information:
Town:

Hangzhou and Shaoxing, China

Kategorie:

Healthcare & Medical

Typ of Press Release: bitte
type of sending: Veröffentlichung

Diese Pressemitteilung wurde bisher 210 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Ascletis' NDA for Its All-oral HCV Treatment Accepted by CFDA"
steht unter der journalistisch-redaktionellen Verantwortung von

Ascletis (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Ascletis Successfully Listed on the Main Board of HKEX ...

HONG KONG, Aug 1, 2018 - (ACN Newswire) - Recently, following the official implementation of the revised listing rules by the Hong Kong Stock Exchange (HKEX), the Hong Kong capital market has been opened up further, welcoming listing applications fro ...

Ascletis-developed Ganovo Acquired Extraordinary Achievement ...

Ganovo Phase III Clinical Study Won the Top Award at the Infectious Disease National Congress of Chinese Medical Association HONG KONG, July 31, 2018 - (ACN Newswire) - Ascletis announced on July 30, 2018 that the Ganovo phase III clinical study w ...

Alle Meldungen von Ascletis